Orphazyme was founded in Denmark in 2009 on a scientific discovery about the role of heat shock proteins (HSPs), which was described in a well-cited article published in the journal Nature.
At 2017 the company was listed at Nasdaq Copenhagen and in May 2022 the company sold all assets and business activities, including those relating to the development and approval of arimoclomol to KemPharm Denmark A/S, a wholly owned subsidiary of KemPharm, Inc.
The Company’s objects are to engage in activities and investments related to biopharmaceutical research and development as well as to carry out any associated activities as deemed relevant by the Board of Directors.. Furthermore, the Company may, within its line of business, participate in partnerships or co-operate with other businesses.
The company is owed by approximately 2200 shareholders.